These findings indicate that CD5 CAR-T-cell therapy can safely elicit clinical responses in patients with CD5-positive T-cell lymphomas without compromising endogenous T cells or increasing the infection risk, although further validation with more patients and extended follow-up is needed. This evidence concerns the gene CD5 and infection.